...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Virology Journal >The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis
【24h】

The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis

机译：乙型肝炎病毒对亚洲丙型肝炎病毒/乙型肝炎病毒合并感染患者抗干扰素和病毒唑抗病毒治疗的影响：荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Clinical and laboratory studies have indicated that coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) can suppress one another, eliciting a dominant disease phenotype. To assess whether HBV can influence the antiviral effect of treatment on HCV, we performed a meta-analysis to comparatively analyze the response to interferon plus ribavirin treatment in patients with HBV/HCV coinfection and HCV mono-infection. Methods Published studies in the English-language medical literature that involved cohorts of HBV/HCV coinfection and HCV mono-infection were obtained by searching Medline, Cochrane and Embase databases. Studies that compared the efficacy of treatment with interferon plus ribavirin in HBV/HCV coinfection and HCV mono-infection were assessed. End-of-treatment virological response (ETVR), sustained virological response (SVR), HCV relapse rate, and alanine aminotransferase (ALT) normalization rate were compared between HBV/HCV coinfection and HCV mono-infection patients. Results Five trials involving 705 patients were analyzed. At the end of follow-up serum ALT normalization rates in patients with HCV mono-infection were significantly higher than in patients with HBV/HCV coinfection (odds ratio (OR)?=?0.56, 95% confidence interval (CI): 0.40–0.80, P?=?0.001). The ETVR and SVR achieved in HBV/HCV coinfection patients were comparable to those in HCV mono-infection patients (OR?=?1.03, 95% CI: 0.37–2.82, P?=?0.96 and OR?=?0.87, 95% CI: 0.62–1.21, P?=?0.38, respectively). The rate of relapse for HCV or HCV genotype 1 was not significantly different between HBV/HCV coinfection patients and HCV mono-infection patients (OR?=?1.55, 95% CI: 0.98–2.47, P?=?0.06; HCV genotype 1: OR?=?2.4, 95% CI: 1.17–4.91, P?=?0.19). Conclusions Treatment with interferon and ribavirin achieves similar ETVR and SVR in HBV/HCV coinfection and HCV mono-infection. HBV/HCV coinfection patients had distinctively lower end of follow-up serum ALT normalization.
机译：背景技术临床和实验室研究表明，乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）的同时感染可以相互抑制，从而引起显性疾病表型。为了评估HBV是否可以影响治疗对HCV的抗病毒作用，我们进行了荟萃分析，以比较分析HBV / HCV合并感染和HCV单一感染患者对干扰素加利巴韦林治疗的反应。方法通过搜索Medline，Cochrane和Embase数据库，获得英语医学文献中涉及HBV / HCV合并感染和HCV单一感染队列的已发表研究。评估了比较干扰素加利巴韦林在HBV / HCV合并感染和HCV单一感染中治疗效果的研究。比较了HBV / HCV合并感染和HCV单一感染患者的治疗终了病毒学应答（ETVR），持续病毒学应答（SVR），HCV复发率和丙氨酸氨基转移酶（ALT）正常化率。结果对5项涉及705例患者的试验进行了分析。随访结束时，HCV单一感染患者的血清ALT正常化率显着高于HBV / HCV合并感染的患者（优势比（OR）≤0.56，95％置信区间（CI）：0.40– 0.80，P≥＝ 0.001）。 HBV / HCV合并感染患者的ETVR和SVR与HCV单一感染患者的ETVR和SVR相当（OR？=？1.03，95％CI：0.37–2.82，P？=？0.96，OR？=？0.87，95％ CI：0.62-1.21，P≥0.38。 HCV或HCV基因型1的复发率在HBV / HCV合并感染患者和HCV单一感染患者之间没有显着差异（OR？=？1.55，95％CI：0.98–2.47，P？=？0.06; HCV基因型1 ：OR？=？2.4，95％CI：1.17–4.91，P？=？0.19）。结论干扰素和利巴韦林的治疗在HBV / HCV合并感染和HCV单一感染中达到了相似的ETVR和SVR。 HBV / HCV合并感染患者的随访血清ALT正常值明显较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号